Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Microbix Biosystems Inc T.MBX

Alternate Symbol(s):  MBXBF

Microbix Biosystems Inc. develops and commercializes biological and technological solutions for human health and wellbeing. It enables the commercialization of diagnostic assays by making a range of critical ingredients and devices for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products (QAPs) that support clinical lab proficiency testing, enable assay development and validation, or help ensure the quality of clinical diagnostic workflows. Its segments include development, manufacturing and sales of products relating to the medical diagnostics industry, namely antigens as test ingredients, quality assessment products to help ensure the accuracy of test workflows and viral transport medium to enable collection of patient test samples and, and development and commercialization of novel and proprietary products or technologies, such as Kinlytic. Its Kinlytic urokinase is a biologic thrombolytic drug used to treat blood clots.


TSX:MBX - Post by User

Bullboard Posts
Comment by longondmxon Jan 06, 2014 3:20pm
141 Views
Post# 22062898

RE:RE:$122,000 isn't a big chew

RE:RE:$122,000 isn't a big chew
Jan 23, 2014 is when the hearing will be held.  I wonder how long it will be before a decision is made.

In any event, I wonder if Novartis will make a play to buy out Microbix.  Clearly they are interested in the technology and the possibilities it brings.  Novartis may even not want to risk proceeding with the hearing and may make a play before hand, rather than risk losing the challenge. 

Figure that a buy out at $50 - 100 million would put MBX stock at 0.75 - $1.50...something that both the acquirer and acquiree could live with.  I know I'd be happy at that price.  On the other hand, the huge earnings potential of this technology alone should bring greater fortunes as time goes on...so whether there is a buyout or not, the real issue hinges on the outcome of that hearing.  Should be an interesting 2 weeks.
Bullboard Posts